BioScience Health Innovations 3Q 2026: Revenue $970.07K, EPS ($0.01) — 10-Q Summary

BioScience Health Innovations reported 3Q 2026 revenue of $970.07K, down 14% YoY, and a net loss of $149,225, wider than the prior year's $8,782. Operating expenses increased to $785,824 due to exchange-listing costs, marketing, R&D, and other factors. Management remains confident in projected growth.

Original reporting
Published Nov 13, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BioScience Health Innovations 3Q 2026: Revenue $970.07K, EPS ($0.01) — 10-Q Summary — source image
Decision brief

The 30-second read

Low
01

Why it matters

The filing provides the first public disclosure of the company's latest financial performance, offering a baseline for valuation and liquidity considerations.

02

Market read

While the numbers are modest, the filing is the first public release of the quarter's data, useful for niche investors.

03

What to watch

Potential upcoming exchange listing could unlock liquidity and valuation upside.

Relevance 5/10Novelty 5/10Timing: after-hours filing

Background

BioScience Health Innovations filed its 10‑Q for Q3 2026, reporting a 14% revenue decline and widened net loss.

Market effects

None significant; micro‑cap biotech sector impact minimal.

No discernible regional effect.

Limited to investors tracking small‑cap SEC filings.

Counterpoint

The modest revenue decline may be temporary; investors could view the expense increase as a long‑term growth investment.

Key entities

  • BioScience Health Innovations, Inc.

    Micro‑cap biotech firm reporting Q3 2026 results.

Related articles

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.

$DISMedAI 8/10

Disney’s Experiences Segment Hit Record Quarterly Revenue of $10.1 Billion as Cruise Days Surged. Can the Momentum Last?

Disney (DIS) reported Q4 2026 revenue of $25.95B, up 16% YoY, with its Experiences segment hitting a record $10.1B. All units grew, with Experiences leading in operating income at $2.25B. Adjusted net income rose 56% to $3.35B, beating estimates. The company plans to invest $60B in Experiences over a decade, focusing on parks and cruises.

$GLADMed

Gladstone Capital (GLAD) Q4 2026 Earnings Call Transcript

Gladstone Capital (GLAD) reported Q4 2026 earnings with net interest margin at 8.2%. Fee income was below average, but incentive fee credit covered 100% of regular distributions. Net asset value declined to $20.77 per share due to unrealized depreciation and a supplemental distribution. Total investment income rose 11.7% for the year, covering distributions at 104.5%. The company discussed its investment strategy and credit management, highlighting its focus on the lower middle market.

$NVDAHighAI 9/10

Nvidia's $130 Billion Forecast Sparks Fresh AI Stock Rally

Nvidia's shares rose 2% premarket after reporting Q3 sales of $115.84B, up 4x, and raising its fiscal 2028 sales growth target to ~75%. The company also guided to a gross margin of 71-72% for the current quarter. AI-related stocks also gained. Nvidia's board is searching for a permanent CEO after rejecting Jensen Huang's return. The company excluded future China shipments from its projections.